NCT05329103 - A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

PEEL-224

Lyophilized powder reconstituted with D5W

DRUG

FOLF+B

infusional 5-FU, LV, and bevacizumab

Trial Locations (7)

COMPLETED

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

RECRUITING

NEXT Virginia, Fairfax

COMPLETED

Carolina BioOncology Institute, Huntersville

COMPLETED

Mary Crowley Cancer Research, Dallas

RECRUITING

Huntsman Cancer Institute, University of Utah, Salt Lake City

RECRUITING

HonorHealth Research Institiute, Scottsdale

RECRUITING

Stanford Cancer Center, Palo Alto